EV/EBITDA Multiple: MoonLake Pharma (MLTX)
MoonLake Immunotherapeutics (MLTX) experienced management provides transparency in immunology trials, leading to the creation of a unique inflammation therapy system. The EV/EBITDA ratio visualizes this trajectory, where 0.00 reflects the metric's baseline. The company is currently relying on organic growth, advancing its developments independently without engaging external partners or M&A transactions.
MoonLake Immunotherapeutics AG (MLTX) - metric breakdowns and financial figures
- market price and analyst price targets:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- debt and liquidity data:
Total Debt to Capital MoonLake Immunotherapeutics|MLTX - Long-Term Debt to Equity|Short-Term Debt to Equity moonlaketx.com|MLTX - Company Cumulative Debt|Debt to Book Capitalization Ratio MoonLake|MLTX - Company Long-Term Debt|Company Short-Term Debts MoonLake Immunotherapeutics|Quick Liquidity moonlaketx.com
- net income and valuation multiples indicators:
MLTX - Net Financial Result|Expected Profit MoonLake Immunotherapeutics|MLTX - Price to Earnings Ratio|Future Price to Earnings MoonLake Immunotherapeutics AG|MLTX - Price/Earnings to Growth Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MoonLake Corp|MLTX - Profit before interest, taxes and amortization|Earnings per share for the last twelve months MoonLake Immunotherapeutics|MLTX - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months moonlaketx.com|MLTX - Earnings per share growth this year|Net earnings per share growth forecast for next year MoonLake Immunotherapeutics
- issuer revenue and sales details:
Initial company analysis:MLTX (MoonLake Immunotherapeutics)
Finding a balance between operational risks and return on capital within the non-cyclical biotech sector of MoonLake Immunotherapeutics (MLTX) requires an analysis of enterprise value relative to EBITDA. By examining the historical EV/EBITDA chart for MoonLake Immunotherapeutics (MLTX), an investor compares market capitalization with debt and actual cash flow, confirming the macro-resilience of a business dependent on clinical success rather than economic cycles.
Who MoonLake Immunotherapeutics competes with
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ascendispharma.com ASND|MDGL - Enterprise Value to EBITDA Ratio|Corcept Therapeutics Corp - EV/EBITDA Multiple|Company Value to EBITDA Rhythm Pharmaceuticals Inc|AKRO (Akero) - Enterprise Value to EBITDA Ratio|MTSR: Enterprise Value to Operating Income Before Depreciation Ratio|CRNX (Crinetics Corp) - EV/EBITDA Multiple|EV/EBITDA Multiple NewAmsterdam Pharma|EV/EBITDA Multiple SLNO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization FOLD (Amicus Therapeutics Inc)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization 89bio.com ETNB|Agios Corp (AGIO) - Company Value to EBITDA|GPCR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MDXG: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|RZLT: EV/EBITDA Multiple|LXRX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MBX Corp|Enterprise Value to EBITDA Ratio Altimmune Corp (ALT)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization aardvarktherapeutics.com (AARD)|Enterprise Value to EBITDA Ratio sagimet.com SGMT|EV/EBITDA Multiple BIOA (BioAge)|Biomea Fusion - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|QNCX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation GUTS (Fractyl)|VTVT (vTv Therapeutics, Inc.) - Enterprise Value to EBITDA Ratio|Agape ATP Corp. (ATPC) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization pluri-biotech.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SYBX|EV/EBITDA Multiple LPCN|Matinas BioPharma Holdings - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple SPRB (sprucebiosciences.com)|Enterprise Value to Operating Income Before Depreciation Ratio GLTO (galecto.com)|CTCX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio LUMO|organovo.com (ONVO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Radius Health - Business Value to Operating Income Before Depreciation
